Bioxcel therapeutics announces fda approval of igalmi™ (dexmedetomidine) sublingual film for acute treatment of agitation associated with schizophrenia or bipolar i or ii disorder in adults

First and only fda-approved orally dissolving sublingual film for mild, moderate or severe agitation in patients with schizophrenia or bipolar i or ii disorder 1

BTAI Ratings Summary

BTAI Quant Ranking